文献速递造血干细胞移植与细胞治疗

如何在高危患者中预防GVHD:移植后环磷酰胺及后续策略

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.
PubMed 文献 · Blood · 2023-01-01

综述指出,移植后环磷酰胺(PTCy)的广泛采用使HLA不合亲缘供者使用率增至与HLA相合同胞供者相当,并推动其向HLA相合移植扩展;阿巴西普和JAK抑制剂与PTCy联合为更安全的移植平台带来希望。作者通过3例病例回顾其在高危GVHD患者中的现代移植策略。

要点

  • 高危GVHD群体包括HLA不合亲缘(单倍体)及不合无关供者、受者高龄、移植后维持治疗、既往检查点抑制剂或自体移植暴露及良性血液病患者。
  • PTCy的广泛采用使HLA不合亲缘供者使用率增至与HLA相合同胞供者相当的水平。
  • 阿巴西普和JAK抑制剂等新药与PTCy联合用于GVHD预防,为更安全的移植平台带来希望。

核心结论

  • PTCy的广泛采用已使HLA不合亲缘供者的使用率增至与HLA相合同胞供者相当的水平。
  • 作者预测PTCy在HLA相合移植中也将被接受。
  • 阿巴西普和JAK抑制剂等新药与PTCy联合为更安全的移植平台带来希望。

研究设计与样本

  • 本文为综述,通过3例说明性病例回顾作者当前在高危GVHD患者中的移植策略。

主要发现

  • 预处理、GVHD预防和抗微生物预防的进步提高了异基因造血干细胞移植的安全性,使每年移植患者数量大幅增加。
  • 新的GVHD危险因素和高危群体包括HLA不合亲缘(单倍体)及不合无关供者、受者高龄、移植后维持治疗、既往检查点抑制剂和自体造血干细胞移植暴露以及良性血液病患者。
  • PTCy的广泛采用已使HLA不合亲缘供者的使用率增至与HLA相合同胞供者相当的水平。
  • 阿巴西普和JAK抑制剂与PTCy联合用于GVHD预防,为更安全的移植平台带来希望。

临床怎么用

  • 作者通过3例病例回顾其当前在高危GVHD患者中使用现代移植手段的移植方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT), leading to a substantial increase in the number of patients transplanted each year. This influx of patients along with progress in remission-inducing and posttransplant maintenance strategies for hematologic malignancies has led to new GVHD risk factors and high-risk groups: HLA-mismatched related (haplo) and unrelated (MMUD) donors; older recipient age; posttransplant maintenance; prior checkpoint inhibitor and autologous HCT exposure; and patients with benign hematologic disorders. Along with the changing transplant population, the field of HCT has dramatically shifted in the past decade because of the widespread adoption of posttransplantation cyclophosphamide (PTCy), which has increased the use of HLA-mismatched related donors to levels comparable to HLA-matched related donors. Its success has led investigators to explore PTCy's utility for HLA-matched HCT, where we predict it will be embraced as well. Additionally, combinations of promising new agents for GVHD prophylaxis such as abatacept and JAK inhibitors with PTCy inspire hope for an even safer transplant platform. Using 3 illustrative cases, we review our current approach to transplantation of patients at high risk of GVHD using our modern armamentarium.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rimando J, McCurdy SR, Luznik L, et al. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023. PMID: 35405017. doi:10.1182/blood.2021015129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。